Home World News EMA Recommends Granting a Marketing Authorisation for Catumaxomab World News EMA Recommends Granting a Marketing Authorisation for Catumaxomab By Ogkologos - November 12, 2024 769 0 Facebook Twitter Google+ Pinterest WhatsApp It is intended for the intraperitoneal treatment of malignant ascites Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR FDA Approves Crizotinib for Children and Young Adults with Relapsed or... January 19, 2021 Drug Combination Shows Promise for Rhabdomyosarcoma, but Can It Get to... December 9, 2022 EMA Recommends Extension of Indications for Atezolizumab September 28, 2020 Does Living Near Power Lines Increase My Risk of Cancer? March 17, 2022 Load more HOT NEWS This Breast Cancer Patient Is Using Boudoir Photography to Reclaim Her... FDA Approves Retifanlimab-dlwr with Carboplatin and Paclitaxel and as a Single... Advances in Treating Kidney Cancer and Metastatic Prostate Cancer: Research from... Cancer and the Holidays
